Extracted from Financial Review today
Fund managers still rate cancer diagnostics specialist Telix Pharmaceuticals, which in August upgraded its full-year revenue forecast following a strong second quarter. Shares in Telix, which floated in 2017 at 65¢ each, are now trading at $18.76. Despite almost doubling its share price this year, investors remain excited as potential US approval for its renal diagnostics application looms.“There is a huge amount of catalyst coming up in the stock,” Hunter says.
____
IMO that's a huge understatement..
More liken to Global dominance in its product range .. an advancement in life changing medicines that according to TLX HQ have no peers currently..
DYOR
Extracted from Financial Review todayFund managers still rate...
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.76 |
Change
0.640(3.18%) |
Mkt cap ! $6.947B | |||
| Open | High | Low | Value | Volume |
| $20.47 | $20.77 | $20.07 | $28.93M | 1.416M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 194 | $20.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.77 | 960 | 1 |
View Market Depth
| Last trade - 16.10pm 26/09/2024 (20 minute delay) ? |
| TLX (ASX) Chart |